News Center
Share the latest news with you
2025
2025-01-22
In January 2025, Senaparib Capsules (派舒宁® ）has received marketing authorization in China from National Medical Products Administration (NMPA) as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
About Us
News Recommendation
Copyright (c) 2013 IMPACT Therapeutics. All Rights Reserved 沪ICP备2024107649号 互联网药品信息证书编号:(沪)-非经营性-2025-0012 /Clinical Trial Privacy Notice / Privacy Notice / Legal Statement
